In a patient with toxic epidermal necrolysis, does intravenous immunoglobulin improve survival compared with supportive care?

Archives of Dermatology

Volumn 147, Issue 12, 2011, Pages 1437-1440

  Wootton, Catriona Isobel ^a   Patel, Anand Neel ^a   Williams, Hywel C ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONSERVATIVE TREATMENT; COOMBS POSITIVE HEMOLYTIC ANEMIA; DEBRIDEMENT; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ERYTHEMA; FLUID BALANCE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALE; MORTALITY; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PLASMAPHERESIS; PRIORITY JOURNAL; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; SYSTEMATIC REVIEW; TEMPERATURE MEASUREMENT; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; WOUND DRESSING;

AGED; ANTICONVULSANTS; BIOPSY; EPIDERMAL NECROLYSIS, TOXIC; EPILEPSY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIAZINES;

EID: 84255171348     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.300     Document Type: Article

References (18)

1. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group (Severe Cutaneous Adverse Reactions). Correlations between clinical patterns and causes of erythema multiforme majus, Stevens- Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019-1024. (Pubitemid 34875605)
2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96. (Pubitemid 23029676)
3. Rajaratnam R, Mann C, Balasubramaniam P, et al. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol. 2010;35(8):853-862.
4. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282 (5388):490-493. (Pubitemid 28483679)
5. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev. 2002;(4):CD001435.
6. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352(9140): 1586-1589. (Pubitemid 28515243)
7. Schneck J, Fagot J-P, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33-40. (Pubitemid 350298143)
8. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol. 2004;43(11):847-851. (Pubitemid 39529949)
9. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens- Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003; 139(1):33-36. (Pubitemid 36091571)
10. Imahara SD, Holmes JH IV, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006; 27(3):270-275. (Pubitemid 43970289)
11. Prins C, Kerdel FA, Padilla RS, et al. TEN-IVIG Study Group (Toxic Epidermal Necrolysis- Intravenous Immunoglobulin). Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139(1):26-32. (Pubitemid 36091570)
12. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25(1):81-88. (Pubitemid 38116760)
13. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004; 25(3):246-255. (Pubitemid 38637782)
14. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol. 2003;139(1):39-43. (Pubitemid 36091572)
15. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71(6):398-400. (Pubitemid 41769422)
16. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47(4):548-552.
17. Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol. 2005;85(6):497-502. (Pubitemid 43087286)
18. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs. 2005;65 (15):2085-2090. (Pubitemid 41475790)